Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) indication : coronary artery disease with or without peripheral artery disease

The CADTH Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be reimbursed in combination with acetylsalicylic acid (ASA; 75 mg to 100 mg) for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in pati...

Full description

Bibliographic Details
Corporate Author: CADTH Canadian Drug Expert Committee
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, November 2018
Edition:Final
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Stroke / Prevention & Control
Canada
Aspirin
Secondary Prevention
Rivaroxaban / Economics
Rivaroxaban / Therapeutic Use
Coronary Artery Disease / Drug Therapy
Cost-benefit Analysis
Myocardial Infarction / Prevention & Control
Ischemia / Prevention & Control
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be reimbursed in combination with acetylsalicylic acid (ASA; 75 mg to 100 mg) for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with concomitant coronary artery disease (CAD) and peripheral artery disease (PAD) if the following condition is met: For patients with concomitant CAD and PAD as defined in the Implementation Considerations
Physical Description:1 PDF file (7 pages)

Similar Items